{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:22:39Z","timestamp":1793215359139,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012507","name":"St George and Sutherland Medical Research Foundation","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100012507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012507","name":"St George and Sutherland Medical Research Foundation","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100012507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012507","name":"St George and Sutherland Medical Research Foundation","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100012507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["Not Available"],"award-info":[{"award-number":["Not Available"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Postgraduate Award, Australian Government"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The secreted phospholipase A\n                    <jats:sub>2<\/jats:sub>\n                    human group IIA (hGIIA) is overexpressed in prostate cancer (PCa), where its expression is closely aligned with malignancy. While its enzymatic activity is important in mediating innate immunity, here we highlight that hGIIA contributes to PCa pathology primarily through specific protein-protein interactions. We have developed cyclic peptides cF and c2, derived from the structure of hGIIA, that selectively inhibit these interactions and inhibit PCa growth. hGIIA interacts directly with epidermal growth factor receptor (EGFR), resulting in increased cytosolic PLA\n                    <jats:sub>2<\/jats:sub>\n                    -\u03b1 activation and prostaglandin E\n                    <jats:sub>2<\/jats:sub>\n                    production, which is suppressed by c2. Further, vimentin was identified to bind hGIIA in PCa cells, modulating hGIIA intracellular trafficking. c2 binds vimentin, blocking this interaction and initiating vimentin-mediated aggresome formation and apoptosis even in the absence of hGIIA. cF and c2 suppress androgen-sensitive, castrate-resistant and androgen-independent models of tumour growth in vivo at doses as low as 0.1\u2009mg\/kg, are non-toxic, orally bioavailable and cell-permeable. Critically, as with hGIIA, EGFR and vimentin are also increasingly expressed as PCa develops, cF and c2 may represent a novel therapeutic option for incurable metastatic castrate resistant PCa. Our findings identify hGIIA as an innate immune effector that regulates both inflammation and PCa progression and describe a novel class of hGIIA protein-protein interaction inhibitor with therapeutic potential in PCa.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08280-x","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:36:14Z","timestamp":1766208974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting secreted PLA2 interactions with EGFR and vimentin to arrest prostate tumour growth"],"prefix":"10.1038","volume":"17","author":[{"given":"Timothy J.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryung Rae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Sajinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadma","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-9917","authenticated-orcid":false,"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Qader","family":"Al Bawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Bahidh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Gratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria George","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyer-Carrive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Pickford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-832X","authenticated-orcid":false,"given":"David G.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Mellick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory James","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry G.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Bret","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-4107","authenticated-orcid":false,"given":"Kieran F.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"8280_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8280_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"JS De Bono","year":"2020","unstructured":"De Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455\u201369.","journal-title":"Nat Rev Cancer"},{"key":"8280_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: Triggers, mechanisms and consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity"},{"key":"8280_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbalip.2007.12.001","volume":"1781","author":"TJ Nevalainen","year":"2008","unstructured":"Nevalainen TJ, Graham GG, Scott KF. Antibacterial actions of secreted phospholipases A2. Biochim Biophys Acta -Mol Cell Biol Lipids. 2008;1781:1\u20139.","journal-title":"Biochim Biophys Acta -Mol Cell Biol Lipids"},{"key":"8280_CR5","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.3390\/molecules26237267","volume":"26","author":"KF Scott","year":"2021","unstructured":"Scott KF, Mann TJ, Fatima S, Sajinovic M, Razdan A, Kim RR, et al. Human group IIA phospholipase A2\u2014Three decades on from its discovery. Molecules. 2021;26:7267. https:\/\/doi.org\/10.3390\/molecules26237267.","journal-title":"Molecules"},{"key":"8280_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3892\/ijo.2014.2486","volume":"45","author":"Z Dong","year":"2014","unstructured":"Dong Z, Meller J, Succop P, Wang J, Wikenheiser-Brocamp K, Starnes S, et al. Secretory phospholipase A2-IIa upregulates HER\/HER2-elicited signaling in lung cancer cells. Int J Oncol. 2014;45:978\u201384.","journal-title":"Int J Oncol"},{"key":"8280_CR7","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1158\/0008-5472.CAN-03-3018","volume":"64","author":"P Sved","year":"2004","unstructured":"Sved P, Scott KF, McLeod D, King NJC, Singh J, Tsatralis T, et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 2004;64:6934\u201340.","journal-title":"Cancer Res"},{"key":"8280_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1074\/jbc.M110.123927","volume":"286","author":"KJ Bryant","year":"2011","unstructured":"Bryant KJ, Bidgood MJ, Lee P-W, Taberner M, Salom C, Kumar V, et al. A Bifunctional role for group IIA secreted phospholipase A(2) in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism. J Biol Chem. 2011;286:2492\u2013503.","journal-title":"J Biol Chem"},{"key":"8280_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181\u201393.","journal-title":"Nat Rev Cancer"},{"key":"8280_CR10","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1074\/jbc.273.23.14411","volume":"27","author":"M Murakami","year":"1998","unstructured":"Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, et al. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 1998;27:14411\u201323.","journal-title":"J Biol Chem"},{"key":"8280_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2005.08.012","volume":"240","author":"Q Dong","year":"2006","unstructured":"Dong Q, Patel M, Scott KF, Graham GG, Russel PJ, Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 2006;240:9\u201316.","journal-title":"Cancer Lett"},{"key":"8280_CR12","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","volume":"111","author":"EA Dennis","year":"2011","unstructured":"Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A(2) enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:6130\u201385.","journal-title":"Chem Rev"},{"key":"8280_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","volume":"311","author":"SJ Nicholls","year":"2014","unstructured":"Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome the VISTA-16 randomized clinical trial. JAMA. 2014;311:252\u201362.","journal-title":"JAMA"},{"key":"8280_CR14","doi-asserted-by":"publisher","first-page":"15269","DOI":"10.1074\/jbc.M112.397893","volume":"288","author":"LK Lee","year":"2013","unstructured":"Lee LK, Bryant KJ, Bouveret R, Lei PW, Duff AP, Harrop SJ, et al. Selective inhibition of human group IIA-secreted phospholipase A(2) (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalisation of hGIIA to vimentin in rheumatoid synoviocytes. J Biol Chem. 2013;288:15269\u201379.","journal-title":"J Biol Chem"},{"key":"8280_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/neuonc\/noq078","volume":"12","author":"M Hernandez","year":"2010","unstructured":"Hernandez M, Martin R, Garcia-Cubillas MD, Maeso-Hernandez P, Nieto ML. Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol. 2010;12:1014\u201323.","journal-title":"Neuro Oncol"},{"key":"8280_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3892\/ijo.2017.3964","volume":"50","author":"S Lu","year":"2017","unstructured":"Lu S, Dong Z. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER\/ERBB-elicited signaling in lung and prostate cancer cells. Int J Oncol. 2017;50:2113\u201322.","journal-title":"Int J Oncol"},{"key":"8280_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"8280_CR18","doi-asserted-by":"publisher","unstructured":"Zheng L, Dou X, Ma X, Qu W, Tang X. Identification of potential key genes and pathways in enzalutamide-resistant prostate cancer cell lines: a bioinformatics analysis with data from the Gene Expression Omnibus (GEO) database. Biomed Res Int 8341097 (2020). https:\/\/doi.org\/10.1155\/2020\/8341097.","DOI":"10.1155\/2020\/8341097"},{"key":"8280_CR19","doi-asserted-by":"publisher","first-page":"23992","DOI":"10.1074\/jbc.271.39.23992","volume":"271","author":"A Tseng","year":"1996","unstructured":"Tseng A, Inglis AS, Scott KF. Native peptide inhibition. Specific inhibition of type II phospholipases A2 by synthetic peptides derived from the primary sequence. J Biol Chem. 1996;271:23992\u20138.","journal-title":"J Biol Chem"},{"key":"8280_CR20","doi-asserted-by":"publisher","first-page":"33156","DOI":"10.1074\/jbc.M101272200","volume":"276","author":"WB Church","year":"2001","unstructured":"Church WB, Inglis AS, Tseng A, Duell R, Lee P-W, Bryant KJ, et al. A novel approach to the design of inhibitors of human secreted phospholipase A(2) based on native peptide inhibition. J Biol Chem. 2001;276:33156\u201364.","journal-title":"J Biol Chem"},{"key":"8280_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.amjmed.2016.03.008","volume":"129","author":"A Grodzinsky","year":"2016","unstructured":"Grodzinsky A, Goyal A, Ghosh K, McCullough PA, Fonarow GC, Mebazaa A, et al. Prevalence and prognosis of hyperkalemia in patients with acute myocardial infarction. Am J Med. 2016;129:858\u201365.","journal-title":"Am J Med"},{"key":"8280_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/bjc.2016.29","volume":"114","author":"NM Byrne","year":"2016","unstructured":"Byrne NM, Nesbitt H, Ming L, McKeown SR, Worthington J, McKenna DJ. Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition. Br J Cancer. 2016;114:659\u201368.","journal-title":"Br J Cancer"},{"key":"8280_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4048\/jbc.2014.17.1.40","volume":"17","author":"KI Kim","year":"2014","unstructured":"Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17:40\u201346.","journal-title":"J Breast Cancer"},{"key":"8280_CR24","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.4049\/jimmunol.161.7.3421","volume":"161","author":"L Thommesen","year":"1998","unstructured":"Thommesen L, Sjursen W, Ga\u030asvik K, Hanssen W, Brekke O-L, Skatteb\u00f8l L, et al. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-\u03baB and expression of ICAM-1. J Immunol. 1998;161:3421\u201330.","journal-title":"J Immunol"},{"key":"8280_CR25","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/carcin\/bgq188","volume":"31","author":"Z Dong","year":"2010","unstructured":"Dong Z, Liu Y, Scott KF, Levin L, Gaitonde K, Bracken RB, et al. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis. 2010;31:1948\u201355.","journal-title":"Carcinogenesis"},{"key":"8280_CR26","doi-asserted-by":"publisher","first-page":"29927","DOI":"10.1074\/jbc.274.42.29927","volume":"274","author":"M Murakami","year":"1999","unstructured":"Murakami M, Kambe T, Shimbara S, Yamamoto S, Kuwata H, Kudo I. Functional association of Type IIA secretory phospholipase A2 with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J Biol Chem. 1999;274:29927\u201336.","journal-title":"J Biol Chem"},{"key":"8280_CR27","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/blood-2002-12-3702","volume":"102","author":"E Boilard","year":"2003","unstructured":"Boilard E, Bourgoin SG, Bernatchez C, Surette ME. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood. 2003;102:2901\u20139.","journal-title":"Blood"},{"key":"8280_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1534-5807(01)00008-9","volume":"1","author":"GG Tall","year":"2001","unstructured":"Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell. 2001;1:73\u201382.","journal-title":"Dev Cell"},{"key":"8280_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.stem.2020.01.018","volume":"26","author":"CS Morrow","year":"2020","unstructured":"Morrow CS, Porter TJ, Xu N, Arndt ZP, Ako-Asare K, Heo HJ, et al. Vimentin coordinates protein turnover at the aggresome during neural stem cell quiescence exit. Cell Stem Cell. 2020;26:558\u201368.","journal-title":"Cell Stem Cell"},{"key":"8280_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/fca.10.118","volume":"7","author":"RS Rosenson","year":"2011","unstructured":"Rosenson RS. After FRANCIS: next steps in the clinical evaluation of varespladib methyl. Future Cardiol. 2011;7:11\u201318.","journal-title":"Future Cardiol"},{"key":"8280_CR31","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.3390\/cells10082059","volume":"10","author":"P Balijepalli","year":"2021","unstructured":"Balijepalli P, Sitton CC, Meier KE. Lysophosphatidic acid signaling in cancer cells: What makes LPA so special?. Cells. 2021;10:2059. https:\/\/doi.org\/10.3390\/cells10082059.","journal-title":"Cells"},{"key":"8280_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152638","volume":"7","author":"E Dor\u00e9","year":"2022","unstructured":"Dor\u00e9 E, Joly-Beauparlent C, Morozumi S, Matthieu A, L\u00e9vesque T, Allaeys I, et al. The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation. JCI Insight. 2022;7:e152638. https:\/\/doi.org\/10.1172\/jci.insight.152638.","journal-title":"JCI Insight"},{"key":"8280_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4049\/jimmunol.174.1.464","volume":"174","author":"F Granata","year":"2005","unstructured":"Granata F, Petraroli A, Boilard E, Bezzine S, Bollinger J, Del Vecchio L. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor. J Immunol. 2005;174:464\u201374.","journal-title":"J Immunol"},{"key":"8280_CR34","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.4049\/jimmunol.164.9.4908","volume":"164","author":"M Triggiani","year":"2000","unstructured":"Triggiani M, Granata F, Oriente A, De Marino V, Gentile M, Calabresi C, et al. Secretory phospholipases A2 induce beta-glucuronidase release and IL-6 production from human lung macrophages. J Immunol. 2000;164:4908\u201315.","journal-title":"J Immunol"},{"key":"8280_CR35","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.4049\/jimmunol.0902501","volume":"184","author":"F Granata","year":"2010","unstructured":"Granata F, Frattini A, Loffrado S, Staiano RI, Petraroli A, Ribatti D, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol. 2010;184:5232\u201341.","journal-title":"J Immunol"},{"key":"8280_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nri3859","volume":"15","author":"EA Dennis","year":"2015","unstructured":"Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15:511\u201323.","journal-title":"Nat Rev Immunol"},{"key":"8280_CR37","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","volume":"117","author":"DS Nielsen","year":"2017","unstructured":"Nielsen DS, Shepherd NE, Xu W, Lucke AJ, Stoermer MJ, Fairlie DP. Orally absorbed cyclic peptides. Chem Rev. 2017;117:8094\u2013128.","journal-title":"Chem Rev"},{"key":"8280_CR38","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1248\/bpb.27.1158","volume":"27","author":"M Murakami","year":"2004","unstructured":"Murakami M, Kudo I. Diversity of Phospholipase A2 Enzymes, Secretory Phospholipase A2. Biol Pharm Bull. 2004;27:1158\u201364.","journal-title":"Biol Pharm Bull"},{"key":"8280_CR39","doi-asserted-by":"publisher","first-page":"25024","DOI":"10.1074\/jbc.M313019200","volume":"279","author":"CM Mounier","year":"2004","unstructured":"Mounier CM, Ghomachi F, Lindsay MR, James S, Singer AG, Parton RG, et al. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha. J Biol Chem. 2004;279:25024\u201338.","journal-title":"J Biol Chem"},{"key":"8280_CR40","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med. 2004;351:1502\u201312.","journal-title":"N Eng J Med"},{"key":"8280_CR41","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","volume":"12","author":"KJ Pienta","year":"2006","unstructured":"Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 2006;12:1665\u201371.","journal-title":"Clin Cancer Res"},{"key":"8280_CR42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/cancers13050937","volume":"13","author":"A Ali","year":"2021","unstructured":"Ali A, Kulik G. Signalling pathways that control apoptosis in prostate cancer. Cancers. 2021;13:937. https:\/\/doi.org\/10.3390\/cancers13050937.","journal-title":"Cancers"},{"key":"8280_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.canlet.2021.07.045","volume":"520","author":"KJ Campbell","year":"2021","unstructured":"Campbell KJ, Leung HY. Evasion of cell death: a contributing factor in prostate cancer development and treatment resistance. Cancer Lett. 2021;520:213\u201321.","journal-title":"Cancer Lett"},{"key":"8280_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G","volume":"28","author":"SR Denmeade","year":"1996","unstructured":"Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996;28:251\u201365.","journal-title":"Prostate"},{"key":"8280_CR45","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033\u20133046.","journal-title":"Cell Mol Life Sci"},{"key":"8280_CR46","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.3390\/cancers13194985","volume":"13","author":"S Usman","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, The M-T, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers. 2021;13:4985. https:\/\/doi.org\/10.3390\/cancers13194985.","journal-title":"Cancers"},{"key":"8280_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbrc.2018.10.199","volume":"507","author":"Y Jiu","year":"2018","unstructured":"Jiu Y. Vimentin intermediate filaments function as a physical barrier during intracellular trafficking of caveolin-1. Biochem Biophys Res Comm. 2018;507:161\u20137.","journal-title":"Biochem Biophys Res Comm"},{"key":"8280_CR48","doi-asserted-by":"publisher","first-page":"7436","DOI":"10.3390\/ijms21207436","volume":"21","author":"X Shi","year":"2020","unstructured":"Shi X, Fan C, Jiu Y. Unidirectional regulation of vimentin intermediate filaments to caveolin-1. Int J Mol Sci. 2020;21:7436. https:\/\/doi.org\/10.3390\/ijms21207436.","journal-title":"Int J Mol Sci"},{"key":"8280_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/10520295.2019.1708971","volume":"95","author":"AO Akinshipo","year":"2020","unstructured":"Akinshipo AO, Effiom OA, Odukoya O, Akintoye SO. Consistency of color-deconvolution for analysis of image intensity of alpha smooth muscle actin-positive myofibroblasts in solid multicystic ameloblastomas. Biotech Histochem. 2020;95:411\u20137.","journal-title":"Biotech Histochem"},{"key":"8280_CR50","doi-asserted-by":"publisher","unstructured":"OECD. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. 2008. https:\/\/doi.org\/10.1787\/9789264070684-en.","DOI":"10.1787\/9789264070684-en"},{"key":"8280_CR51","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.4049\/jimmunol.165.5.2790","volume":"165","author":"MJ Bidgood","year":"2000","unstructured":"Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol. 2000;165:2790\u20137.","journal-title":"J Immunol"},{"key":"8280_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"J-P Concordet","year":"2018","unstructured":"Concordet J-P, Haeussler M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:242\u20135.","journal-title":"Nucleic Acids Res"},{"key":"8280_CR53","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41596-018-0026-5","volume":"13","author":"S Ranjit","year":"2018","unstructured":"Ranjit S, Malacrida L, Jameson DM, Gratton E. Fit-free analysis of fluorescence lifetime imaging data using the phasor approach. Nat Protoc. 2018;13:1979\u20132004.","journal-title":"Nat Protoc"},{"key":"8280_CR54","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1529\/biophysj.103.038422","volume":"86","author":"SV Costes","year":"2004","unstructured":"Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J. 2004;86:3993\u20134003.","journal-title":"Biophys J"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08280-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:03:55Z","timestamp":1770303835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08280-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8280"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08280-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KFS, WBC and PdS are shareholders of Filamon Ltd., which owns intellectual property relating to the use of small peptides and other compounds in the diagnosis and treatment of human disease. None of the employers or funders had any role in the compilation of this manuscript, data collection and analysis, decision to publish or preparation of the manuscript. All other authors declare no potential competing financial, non-financial, professional or personal interests relating to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal studies were conducted according to the National Health and Medical Research, Australia guidelines. Details of ethics approvals are in Materials and Methods.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"183"}}